History
Summary of ProstaLund's historical development
2024
First 10 CoreTherm® Eagle machines manufactured.
MDR and ISO13485 certificates from TÜV SÜD.
Start-up of CoreTherm® treatments in Austria.
Published study confirms the good effect of transurethral intraprostatic anesthesia (TUIA) via our Schelin Catheter®.
First published report on transurethral intraprostatic anesthesia (TUIA) via the Schelin Catheter® for holmium laser enucleation of the prostate.
2023
The first study where Schelin Catheter® was used before water vapor therapy is published.
Sergelkliniken in Stockholm starts up with CoreTherm® treatments.
Carlshamns Specialistklinik starts up with CoreTherm® treatments.
CE approval under MDR for CoreTherm® Eagle treatment platform.
Signs distribution agreement with Poland.
Schelin Catheter® approved in Hainan, China and in Switzerland.
First Schelin Catheter®-assisted TURP surgeries performed in Brazil.
Patent for CoreFlow Soft Stent approved in China.
Signs sales agent agreement for France.
First sales of Schelin Catheter® in Austria.
Esbjerg Hospital starts up with CoreTherm® treatments.
2022
Signs distribution agreements with UK, Israel, Brazil, Spain, China, and Italy.
Schelin Catheter® & CoreFlow® Soft Stent are used in conjunction with other BPE treatments for the first time.
A registry study is presented at the Swedish Urology Days showing a lower risk of prostate cancer and related mortality with CoreTherm® than TUR-P.
Dr. Fredrik Stenmark gets a study published showing that CoreTherm® has eminent long-term results in patients with a prostate larger than 80 g.
2021
Becomes Nordic distributor of the flow meter Oruflow.
2020
Launches the product CoreFlow® Soft Stent and receives CoreTherm® agreements with private healthcare providers in Stockholm.
2019
The company changes its strategy and decides to focus on the Nordic countries.
2018 - 2019
ProstaLund switched its stock market from Spotlight to Nasdaq First North Growth Market.
The Specialty Council in Urology in the Stockholm Region highlights TUMT (transurethral microwave therapy, CoreTherm®) as a well-established and evidence-based minimally invasive treatment that is well suited for outpatient specialist care.
In a long-term follow-up, the County Hospital in Kalmar shows that CoreTherm® patients have just as good long-term results as those who have had a surgical procedure. CoreTherm® is becoming increasingly accepted within the urology society in the Nordic region.
Agreement signed with Norway's largest private urology clinic.
2012
Magnus Bolmsjö, founder of ProstaLund and its CEO between the years 2003 – 2006 is engaged by the new owners to lead the restart and move to Lund. Focus on building up the sales organization. The company also initiated research to investigate CoreTherm's effect on prostate cancer.
2009
The owners and the board of directors who were responsible for the move to Uppsala are leaving the company. The new major owners will be Bo Håkansson and William Gunnarsson.
2006
New ownership structure, management, and board move operations from Lund to Uppsala.
2005
Start-up of own sales company in Orlando, USA.
2003
Schelin Catheter was CE marked.
2002
FDA approval and start operations in the US. Agreements are made with a major US distributor for the US.
1998
CE brand of CoreTherm.
1991
The company is founded by Associate Professor Magnus Bolmsjö in Lund.